Market Risers: Allergy Therapeutics, AstraZeneca, Bunzl

Broker Ratings

Shares of Allergy Therapeutics with EPIC code: LON:AGY has risen 3.55% or 1.25 points during the course of today’s session so far. Investors have stayed positive while the stock has been in play. The high for the period has peaked at 36.5 dipping to 35. The volume total for shares traded up to this point was 284,040 with the average number of shares traded daily being 506,977. The 52 week high is 40.5 about 5.25 points difference from the previous close and the 52 week low at 12.75 is a variance of 22.5 points. Allergy Therapeutics has a 20 SMA of 36.91 and now the 50 day SMA of 36.08. Market capitalisation is now £234.26m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Allergy Therapeutics being recorded at Tuesday, November 2, 2021 at 12:36:28 PM GMT with the stock price trading at 36.5 GBX.

Stock in AstraZeneca found using EPIC: LON:AZN has gained 1.12% or 102 points during the course of today’s session so far. Investors have stayed positive while the stock has been in play. The period high has peaked at 9275 meanwhile the session low reached 9157.81. Volume total for shares traded at this point reached 308,872 whilst the daily average number of shares exchanged is just 1,901,970. The 52 week high for the shares is 9275 some 137 points different to the previous business close and a 52 week low sitting at 6736 a difference of some 2402 points. AstraZeneca now has a 20 SMA at 8962.84 and now the 50 day moving average now at 8747.35. This puts the market capitalisation now at £144,185.74m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Tuesday, November 2, 2021 at 12:35:26 PM GMT with the stock price trading at 9240 GBX.

Stock in Bunzl with EPIC code: LON:BNZL has risen 1.33% or 36 points throughout today’s trading session so far. Buyers have remained optimistic throughout the session. Range high for the period so far is 2745 and a low of 2690. Volume total for shares traded at this point reached 228,634 with the daily average at 699,886. The 52 week high price for the shares is 2745 about 43 points in difference to the previous days close of business and a 52 week low sitting at 2122 making a difference of 580 points. Bunzl now has a 20 SMA at 2552.61 and now a 50 day MA at 2570.22. This puts the market capitalisation now at £9,260.41m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Bunzl being recorded at Tuesday, November 2, 2021 at 12:31:23 PM GMT with the stock price trading at 2738 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death.

AstraZeneca’s Tezspire meets key endpoints in Phase III EoE trial

AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52.

AstraZeneca strengthens funding position with €2.55 billion Eurobond issue

AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026.

AstraZeneca reports positive Phase III results for Tagrisso-Orpathys lung cancer combination

Astrazeneca Plc has reported positive SAFFRON Phase III results for Tagrisso and Orpathys, showing improved progression-free and overall survival.

AstraZeneca H1 2026 revenue rises 9% as growth momentum continues

AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease offset Farxiga and China headwinds. The company raised its interim dividend, secured 30 approvals, and reaffirmed full-year guidance and its $80 billion 2030 revenue goal.

Astrazeneca reports positive survival data for Sone-Ve in gastric cancer trial

Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial.

Search